Association of Intravenous Magnesium Sulfate With Mortality in Patients With Myocardial Infarction: A Retrospective Cohort Study.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as an observational study.

This study aimed to evaluate the association of intravenous magnesium sulfate administration on 28-day all-cause mortality among patients with acute myocardial infarction across different time windows of treatment initiation.

Adjusted Kaplan-Meier survival curve analysis and log-rank test were used to evaluate the association between intravenous magnesium sulfate administration and long-term mortality risk.

Landmark analysis was performed to assess both short-term and long-term connections.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

This retrospective observational cohort study analyzed data from patients diagnosed with acute type 1 myocardial infarction using the Medical Information Marketplace in Intensive Care (MIMIC)-IV database.

Patients were categorized into five groups based on the timing of magnesium sulfate initiation: Q1 (not received), Q2 (≤ 2 h), Q3 (2-6 h), Q4 (6-12 h), and Q5 (≥ 12 h).

How the Study Was Run

The primary outcome was 28-day all-cause mortality, while the secondary outcome was one-year all-cause mortality.

Restricted mean survival time (RMST) was calculated as part of the sensitivity analysis to further investigate treatment correlations.

What Was Measured

PubMed files the paper under topics including Magnesium Sulfate, Myocardial Infarction, Databases, Factual, Risk Factors, Administration, Intravenous and Risk Assessment.

Author keywords: Acute myocardial infarction and All-cause mortality.

What This Means in Plain Language

This is an observational study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Cardiovascular drugs and therapy), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.